Acute Myeloid Leukemia Clinical Trials

162 studies are recruiting for acute myeloid leukemia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 6

1. Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

   Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in leukemic and myelodysplastic patients who have had a partial…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   University of Kansas Cancer Center, Westwood, Kansas

   Locations

   2 in total

   Run by

   University of Kansas Medical Center

   See if you can join NCT03533816 on ClinicalTrials.gov

2. Revumenib in Combination With 7+3 + Midostaurin in AML

   This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaur…

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   2 in total

   Run by

   Richard Stone, MD

   See if you can join NCT06313437 on ClinicalTrials.gov

3. Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

   The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   2 in total

   Run by

   Remedy Plan, Inc.

   See if you can join NCT07107126 on ClinicalTrials.gov

4. Ziftomenib Maintenance Post Allo-HCT

   The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT06440135 on ClinicalTrials.gov

5. A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

   Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in pat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic - Phoenix, Phoenix, Arizona

   Locations

   44 in total

   Run by

   Kura Oncology, Inc.

   See if you can join NCT05735184 on ClinicalTrials.gov

6. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

   This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cel…

   Stage

   Phase 2

   Ages

   1 to 60

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   3 in total

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT03970096 on ClinicalTrials.gov

7. A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

   The purpose of this study is to test the safety of ADCLEC.syn1 CAR T cells in people with relapsed or refractory AML. The researchers will try to find the highest dose of ADCLEC.syn1 CAR T cells that causes few or mild side effects in participants. Once the researchers find this dose, it will test …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05748197 on ClinicalTrials.gov

8. CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

   This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. Th…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   3 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06059391 on ClinicalTrials.gov

9. CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

   This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment i…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Run by

   City of Hope Medical Center

   See if you can join NCT05672147 on ClinicalTrials.gov

10. Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

    This phase I trial tests the safety, side effects, and effectiveness of olutasidenib in preventing the return of disease (relapse) in patients who have undergone donor (allogeneic) hematopoietic cell transplant for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocy…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    2 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06543381 on ClinicalTrials.gov

11. Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

    This phase I trial tests the safety, side effects, best dose and effectiveness of revumenib in treating patients with acute leukemia after allogeneic stem cell transplant. Revumenib is in a class of medications called menin inhibitors. Revumenib targets and binds to the protein menin, thereby preve…

    Stage

    Phase 1

    Ages

    2 and older

    Site

    City of Hope Medical Center, Duarte, California

    Run by

    City of Hope Medical Center

    See if you can join NCT06575296 on ClinicalTrials.gov

12. Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

    The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT07044544 on ClinicalTrials.gov

13. FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia

    This is a Phase 1, uncontrolled, single-arm, open-label, nonrandomized, dose escalation, study of Decitabine (DAC)+Venetoclax (VEN)+FHD-286 in participants with newly diagnosed Acute Myeloid Leukemia (AML) classified as adverse risk per the 2022 European Leukemia Net (ELN) criteria or AML that has …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Montefiore Medical Center, The Bronx, New York

    Run by

    Montefiore Medical Center

    See if you can join NCT07283094 on ClinicalTrials.gov

14. CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

    The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.

    Stage

    Phase 1

    Ages

    18 to 70

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT05558124 on ClinicalTrials.gov

15. Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

    The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06511882 on ClinicalTrials.gov

16. Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)

    The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML). A secondary objective is to assess efficacy of the CIML-NK cells in treat…

    Stage

    Phase 1

    Ages

    2 and older

    Site

    Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

    Run by

    Children's Hospital Medical Center, Cincinnati

    See if you can join NCT05580601 on ClinicalTrials.gov

17. A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

    This is a first-in-human, multicenter, open-label, phase 1 study to evaluate the safety, PK, PD and preliminary efficacy of STX-0712 in patients with advanced CMML and AML for whom there are no further treatment options known to confer clinical benefit.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford University, Stanford, California

    Locations

    7 in total

    Run by

    Solu Therapeutics, Inc

    See if you can join NCT06950034 on ClinicalTrials.gov

18. Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

    Treatment with olutasidenib for isocitrate dehydrogenase 1 (IDH1) mutant acute myeloid leukemia (AML) after completion of traditional intensive induction/consolidation is likely to be safe, tolerable, and may provide clinical benefit in terms of maintenance of remission and perhaps improvement in s…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Virginia Commonwealth University, Richmond, Virginia

    Run by

    Virginia Commonwealth University

    See if you can join NCT07130695 on ClinicalTrials.gov

19. Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

    This is a Phase I, open-label, non-randomized, dose escalation study in adolescents and adults with relapsed/refractory acute myeloid leukemia, acute lymphoblastic leukemia, or mixed phenotype acute leukemia. Patients will receive continuous oral MRX-2843 in 28 day cycles at predefined dose cohorts.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Emory University - WINSHIP Cancer Center, Atlanta, Georgia

    Locations

    3 in total

    Run by

    Meryx, Inc.

    See if you can join NCT04872478 on ClinicalTrials.gov

20. Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

    This is a Phase 1b, open-label study evaluating Venetoclax in combination with intensive induction and consolidation chemotherapy in previously untreated, adult patients with acute myeloid leukemia. In Part 1, the dose escalation phase, the safety and tolerability of the combination with Venetoclax…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM), The Bronx, New York

    Run by

    Montefiore Medical Center

    See if you can join NCT05342584 on ClinicalTrials.gov

21. Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    This study aims to learn about the safety, tolerability, and different dose levels' safety profiles of Venetoclax and Bomedemstat (VenBom) combination therapy in participants with relapsed or refractory acute myeloid leukemia.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Miami, Miami, Florida

    Run by

    Terrence J Bradley, MD

    See if you can join NCT05597306 on ClinicalTrials.gov

22. Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

    Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure. The bone marrow is the place or factory in the body where components of blood such as red cells, platelets and white cells are made. In…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California Davis Health (UC Davis Health), Sacramento, California

    Locations

    3 in total

    Run by

    Montefiore Medical Center

    See if you can join NCT05184842 on ClinicalTrials.gov

23. PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

    A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product th…

    Stage

    Phase 1

    Ages

    Up to 30

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT05105152 on ClinicalTrials.gov

24. Home Blood Transfusions

    This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Parti…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT07121140 on ClinicalTrials.gov

25. Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

    This is a Phase 1 study investigating the safety and efficacy of Danvatirsen as a monotherapy followed by combination with Venetoclax in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Funding Source: FDA OOPD

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Montefiore Medical Center, The Bronx, New York

    Locations

    2 in total

    Run by

    Montefiore Medical Center

    See if you can join NCT05986240 on ClinicalTrials.gov